Summary:
In patients with pituitary macroadenomas, gadobutrol significantly improved the evaluation of quantitative perfusion parameters compared to meglumine gadoterate, though it was associated with no significant differences in adverse effects.
| PICO | Description |
|---|---|
| Population | Patients with pituitary macroadenomas undergoing dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). |
| Intervention | Administration of gadobutrol, a macrocyclic non-ionic contrast agent, for DCE-MRI. |
| Comparison | Administration of meglumine gadoterate, a macrocyclic ionic contrast agent, for DCE-MRI. |
| Outcome | Gadobutrol enhanced the evaluation of pituitary macroadenoma perfusion parameters compared to meglumine gadoterate. No significant differences in adverse effects or safety profiles were observed between the two contrast agents. |
Source: Kihwan Hwang, et al. “Comparison of gadobutrol and meglumine gadoterate for dynamic contrast-enhanced MRI of pituitary macroadenomas.” Read article here.
